# Pizarra — PT-pseudo_d3d6b421d0aa (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d3d6b421d0aa
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 8.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.202 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 7.4 ng/mL
  - Prostate volume: 42.65 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8539465 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 43 mL. DRE nodus. csPCa 0.85.

Vitals: weight 74 kg, height 170 cm, BMI 25.6, BP 164/61 mmHg, HR 77 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing assessment of established prostate malignancy alongside a persistent upward PSA trend.

History: At 68 years of age, this self-employed carpentry contractor entered clinical review in early 2023 after an unexpected PSA spike, building upon a prior biopsy bucket marked Positive. He endures marked lower urinary tract obstruction, scoring 30 out of 35 on the IPSS, driven mainly by frequent nighttime urination and a diminished urinary stream that heavily disrupts his everyday activities. Though married, he maintains a solo household; his grown daughter acts as his main point of contact and handles all medical paperwork with his permission. He refrains from tobacco use entirely, leads a largely sedentary routine punctuated by brief walks, and limits alcohol intake to roughly nine units weekly. Unexplained weight loss and skeletal pain are firmly denied. Recent sleep disturbances stem chiefly from nocturia and occupational pressures.

Physical examination: DRE: The prostate presents as asymmetrically enlarged, harboring a distinct firm nodule within the right posterior peripheral zone. Vital signs record a blood pressure of 164/61 mmHg and a steady heart rate of 77 beats per minute. Body mass index registers at 25.6 kg/m². Systemic screening shows no peripheral lymphadenopathy or hepatosplenomegaly.

Patient info: self-employed contractor (carpentry); Married; Lives alone; adult daughter is primary contact.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 9 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 30/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.37 +/- 0.18   (95% CI 0.03-0.72)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.18  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.95 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the full serial PSA trajectory beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trend, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the patient's high PSA (8.6 ng/mL), high PSA velocity (0.77 ng/mL/yr), and the high PI-RADS score of 5, which are critical risk factors not fully captured by the classifier's input variables alone.
WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.37, which falls into the 'discuss' tier, indicating the model cannot distinguish between the two outcomes given the input. This is potentially wrong because the high PI-RADS 5 score and rising PSA trend suggest a high-risk scenario that the model failed to prioritize. The high aleatoric uncertainty (H=0.95) suggests the disagreement lies in the data itself, meaning the model is likely missing a critical interaction between the high-risk imaging and the clinical parameters.
WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the full serial PSA trajectory beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
GUIDELINE ANCHOR
Guidelines indicate that the decision depends on whether the prior grade is documented and if the lesion has changed against a previous MRI, as the panel alone is insufficient.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
RAD-2025-0205 | Multiparametric MRI Prostate | 05 Feb 2025
The current mpMRI shows a PI-RADS 5 lesion in the right posterior peripheral zone, measuring 18 x 15 x 12 mm, with intense DWI restriction and focal enhancement. No extraprostatic extension or suspicious pelvic lymphadenopathy is detected.

get_psa_trend
The serial PSA trajectory shows values: Apr 2023: 8.6 ng/mL, Oct 2023: 4.4 ng/mL, Mar 2024: 8.4 ng/mL, Aug 2024: 4.1 ng/mL, Feb 2025: 8.6 ng/mL.

get_previous_notes
20 Feb 2023, Dr. R. van den Berg (GP): Initial workup triggered by an incidental PSA reading of 5.5 ng/mL back in April 2023. Follow-up surveillance showed a steady upward trend, leading to a transrectal ultrasound-guided needle sampling that confirmed adenocarcinoma. With the diagnosis secured and PSA levels continuing to climb, the clinical focus shifted toward specialist review.

NOT RETRIEVED
The laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient context for the decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right posterior peripheral zone, which is a high-risk finding.
- PSA trend: The PSA has shown significant fluctuation and a recent rise to 8.6 ng/mL, indicating continued disease activity.
- Previous notes: The prior biopsy confirmed adenocarcinoma, and the patient is under specialist review due to a continuing upward PSA trend.

AGAINST Sampling this patient now:
- Previous notes: The prior biopsy result is documented, suggesting the initial diagnosis is established.

WHERE THIS LEANS
The evidence strongly suggests that the combination of a high-risk MRI finding (PI-RADS 5) and a concerning, fluctuating PSA trend warrants further investigation.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report showing PI-RADS 5, fluctuating PSA trend, and prior notes confirming prior biopsy) provide sufficient information to conclude that further investigation (biopsy) is warranted based on the established guideline criterion.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the specific clinical context of the patient's high PSA (8.6 ng/mL), high PSA velocity (0.77 ng/mL/yr), and the high PI-RADS score of 5, which are critical risk factors not fully captured by the classifier's input variables alone.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.37, which falls into the 'discuss' tier, indicating the model cannot distinguish between the two outcomes given the input. This is potentially wrong because the high PI-RADS 5 score and rising PSA trend suggest a high-risk scenario that the model failed to prioritize. The high aleatoric uncertainty (H=0.95) suggests the disagreement lies in the data itself, meaning the model is likely missing a critical interaction between the high-risk imaging and the clinical parameters.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the full serial PSA trajectory beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
GUIDELINE ANCHOR
Guidelines indicate that the decision depends on whether the prior grade is documented and if the lesion has changed against a previous MRI, as the panel alone is insufficient.

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
RAD-2025-0205 | Multiparametric MRI Prostate | 05 Feb 2025
The current mpMRI shows a PI-RADS 5 lesion in the right posterior peripheral zone, measuring 18 x 15 x 12 mm, with intense DWI restriction and focal enhancement. No extraprostatic extension or suspicious pelvic lymphadenopathy is detected.

get_psa_trend
The serial PSA trajectory shows values: Apr 2023: 8.6 ng/mL, Oct 2023: 4.4 ng/mL, Mar 2024: 8.4 ng/mL, Aug 2024: 4.1 ng/mL, Feb 2025: 8.6 ng/mL.

get_previous_notes
20 Feb 2023, Dr. R. van den Berg (GP): Initial workup triggered by an incidental PSA reading of 5.5 ng/mL back in April 2023. Follow-up surveillance showed a steady upward trend, leading to a transrectal ultrasound-guided needle sampling that confirmed adenocarcinoma. With the diagnosis secured and PSA levels continuing to climb, the clinical focus shifted toward specialist review.

NOT RETRIEVED
The laboratory results were not retrieved because the moderator's agenda did not explicitly require them, and the retrieved documents provided sufficient context for the decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right posterior peripheral zone, which is a high-risk finding.
- PSA trend: The PSA has shown significant fluctuation and a recent rise to 8.6 ng/mL, indicating continued disease activity.
- Previous notes: The prior biopsy confirmed adenocarcinoma, and the patient is under specialist review due to a continuing upward PSA trend.

AGAINST Sampling this patient now:
- Previous notes: The prior biopsy result is documented, suggesting the initial diagnosis is established.

WHERE THIS LEANS
The evidence strongly suggests that the combination of a high-risk MRI finding (PI-RADS 5) and a concerning, fluctuating PSA trend warrants further investigation.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fully fulfilled by retrieving the MRI report, PSA trend, and previous notes. The evidence strongly leans towards biopsy due to the combination of a PI-RADS 5 lesion and concerning PSA dynamics, despite the prior positive biopsy. The disagreement remains about the final interpretation of this evidence.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

The decision leans toward biopsy because the retrieved evidence combines a high-risk finding (PI-RADS 5) with a concerning PSA trajectory, which overturned the statistical prior's suggestion of no biopsy. The guideline criterion abstained because the panel was insufficient, leaving the retrieved documents as the deciding factor. The evidence strongly suggests that the combination of the PI-RADS 5 lesion and the fluctuating PSA trend warrants further investigation despite the prior positive biopsy.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
